O	0	9	Increased	Increase	VBN	B-NP
O	10	14	nm23	nm23	NN	I-NP
O	14	15	-	-	HYPH	I-NP
O	15	17	H1	H1	NN	I-NP
O	18	21	and	and	CC	I-NP
O	22	26	nm23	nm23	NN	I-NP
O	26	27	-	-	HYPH	B-NP
O	27	29	H2	H2	NN	I-NP
O	30	39	messenger	messenger	NN	I-NP
O	40	43	RNA	RNA	NN	I-NP
O	44	54	expression	expression	NN	I-NP
O	55	58	and	and	CC	O
O	59	66	absence	absence	NN	B-NP
O	67	69	of	of	IN	B-PP
O	70	79	mutations	mutation	NNS	B-NP
O	80	82	in	in	IN	B-PP
B-Cancer	83	88	colon	colon	NN	B-NP
I-Cancer	89	99	carcinomas	carcinoma	NNS	I-NP
O	100	102	of	of	IN	B-PP
O	103	106	low	low	JJ	B-NP
O	107	110	and	and	CC	I-NP
O	111	115	high	high	JJ	I-NP
O	116	126	metastatic	metastatic	JJ	I-NP
O	127	136	potential	potential	NN	I-NP
O	136	137	.	.	.	O

O	139	149	BACKGROUND	BACKGROUND	NN	B-NP
O	149	150	:	:	:	O
O	151	154	The	The	DT	B-NP
O	155	161	murine	murine	JJ	I-NP
O	162	166	nm23	nm23	NN	I-NP
O	167	171	gene	gene	NN	I-NP
O	172	182	suppresses	suppress	VBZ	B-VP
O	183	186	the	the	DT	B-NP
O	187	197	metastatic	metastatic	JJ	I-NP
O	198	206	behavior	behavior	NN	I-NP
O	207	209	of	of	IN	B-PP
B-Cell	210	219	malignant	malignant	JJ	B-NP
I-Cell	220	226	rodent	rodent	NN	I-NP
I-Cell	227	232	tumor	tumor	NN	I-NP
I-Cell	233	238	lines	line	NNS	I-NP
O	238	239	,	,	,	O
O	240	243	and	and	CC	O
O	244	251	reduced	reduce	VBD	B-VP
O	252	256	nm23	nm23	NN	B-NP
O	257	267	expression	expression	NN	I-NP
O	268	278	correlates	correlate	VBZ	B-VP
O	279	283	with	with	IN	B-PP
O	284	293	increased	increase	VBN	B-NP
O	294	304	likelihood	likelihood	NN	I-NP
O	305	307	of	of	IN	B-PP
B-Cancer	308	313	lymph	lymph	NN	B-NP
I-Cancer	314	318	node	node	NN	I-NP
I-Cancer	319	329	metastases	metastasis	NNS	I-NP
O	330	332	in	in	IN	B-PP
O	333	338	human	human	JJ	B-NP
B-Cancer	339	345	breast	breast	NN	I-NP
I-Cancer	346	353	cancers	cancer	NNS	I-NP
O	353	354	.	.	.	O

O	355	359	More	More	RBR	B-NP
O	360	366	recent	recent	JJ	I-NP
O	367	371	data	datum	NNS	I-NP
O	372	376	have	have	VBP	B-VP
O	377	389	demonstrated	demonstrate	VBN	I-VP
O	390	393	the	the	DT	B-NP
O	394	403	existence	existence	NN	I-NP
O	404	406	of	of	IN	B-PP
O	407	410	two	two	CD	B-NP
O	411	416	human	human	JJ	I-NP
O	417	421	nm23	nm23	NN	I-NP
O	422	426	gene	gene	NN	I-NP
O	427	437	homologues	homologue	NNS	I-NP
O	437	438	,	,	,	O
O	439	443	nm23	nm23	NN	B-NP
O	443	444	-	-	HYPH	I-NP
O	444	446	H1	H1	NN	I-NP
O	447	450	and	and	CC	I-NP
O	451	455	nm23	nm23	NN	I-NP
O	455	456	-	-	HYPH	B-NP
O	456	458	H2	H2	NN	I-NP
O	458	459	,	,	,	O
O	460	463	and	and	CC	O
O	464	468	have	have	VBP	B-VP
O	469	474	shown	show	VBN	I-VP
O	475	479	that	that	IN	B-SBAR
O	480	488	deletion	deletion	NN	B-NP
O	489	491	of	of	IN	B-PP
O	492	496	nm23	nm23	NN	B-NP
O	496	497	-	-	HYPH	B-NP
O	497	499	H1	H1	NN	I-NP
O	500	507	alleles	allele	NNS	I-NP
O	508	514	occurs	occur	VBZ	B-VP
O	515	517	in	in	IN	B-PP
O	518	522	some	some	DT	B-NP
B-Cancer	523	528	colon	colon	NN	I-NP
I-Cancer	529	539	carcinomas	carcinoma	NNS	I-NP
O	540	550	associated	associate	VBN	B-VP
O	551	555	with	with	IN	B-PP
O	556	560	poor	poor	JJ	B-NP
O	561	570	prognosis	prognosis	NN	I-NP
O	570	571	.	.	.	O

O	572	577	These	These	DT	B-NP
O	578	586	findings	finding	NNS	I-NP
O	587	594	suggest	suggest	VBP	B-VP
O	595	599	that	that	IN	B-SBAR
O	600	604	nm23	nm23	NN	B-NP
O	604	605	-	-	HYPH	B-NP
O	605	607	H1	H1	NN	I-NP
O	608	615	encodes	encode	VBZ	B-VP
O	616	619	for	for	IN	B-PP
O	620	631	suppression	suppression	NN	B-NP
O	632	634	of	of	IN	B-PP
B-Cancer	635	640	colon	colon	NN	B-NP
I-Cancer	641	650	carcinoma	carcinoma	NN	I-NP
O	651	661	metastasis	metastasis	NN	I-NP
O	661	662	.	.	.	O

O	663	665	In	In	IN	B-PP
O	666	674	contrast	contrast	NN	B-NP
O	674	675	,	,	,	O
O	676	678	we	we	PRP	B-NP
O	679	683	have	have	VBP	B-VP
O	684	694	previously	previously	RB	I-VP
O	695	703	reported	report	VBN	I-VP
O	704	708	that	that	IN	B-SBAR
O	709	714	total	total	JJ	B-NP
O	715	719	nm23	nm23	NN	I-NP
O	720	729	messenger	messenger	NN	I-NP
O	730	733	RNA	RNA	NN	I-NP
O	734	735	(	(	(	O
O	735	739	mRNA	mRNA	NN	B-NP
O	739	740	)	)	)	O
O	741	751	expression	expression	NN	B-NP
O	752	754	is	be	VBZ	B-VP
O	755	764	increased	increase	VBN	I-VP
O	765	767	to	to	TO	B-PP
O	768	775	similar	similar	JJ	B-NP
O	776	782	levels	level	NNS	I-NP
O	783	785	in	in	IN	B-PP
B-Cancer	786	791	colon	colon	NN	B-NP
I-Cancer	792	798	tumors	tumor	NNS	I-NP
O	799	801	of	of	IN	B-PP
O	802	806	both	both	CC	B-NP
O	807	811	high	high	JJ	I-NP
O	812	815	and	and	CC	I-NP
O	816	819	low	low	JJ	I-NP
O	820	830	metastatic	metastatic	JJ	I-NP
O	831	840	potential	potential	NN	I-NP
O	840	841	.	.	.	O

O	842	849	PURPOSE	PURPOSE	NN	B-NP
O	849	850	:	:	:	O
O	851	855	This	This	DT	B-NP
O	856	861	study	study	NN	I-NP
O	862	865	was	be	VBD	B-VP
O	866	874	designed	design	VBN	I-VP
O	875	877	to	to	TO	B-VP
O	878	887	reconcile	reconcile	VB	I-VP
O	888	891	our	our	PRP$	B-NP
O	892	900	previous	previous	JJ	I-NP
O	901	909	findings	finding	NNS	I-NP
O	910	914	with	with	IN	B-PP
O	915	918	the	the	DT	B-NP
O	919	925	recent	recent	JJ	I-NP
O	926	932	report	report	NN	I-NP
O	933	935	of	of	IN	B-PP
O	936	940	nm23	nm23	NN	B-NP
O	940	941	-	-	HYPH	B-NP
O	941	943	H1	H1	NN	I-NP
O	944	951	allelic	allelic	JJ	I-NP
O	952	960	deletion	deletion	NN	I-NP
O	961	963	in	in	IN	B-PP
O	964	969	human	human	JJ	B-NP
B-Cancer	970	975	colon	colon	NN	I-NP
I-Cancer	976	983	cancers	cancer	NNS	I-NP
O	984	994	associated	associate	VBN	B-VP
O	995	999	with	with	IN	B-PP
O	1000	1004	poor	poor	JJ	B-NP
O	1005	1014	prognosis	prognosis	NN	I-NP
O	1014	1015	.	.	.	O

O	1016	1019	Our	Our	PRP$	B-NP
O	1020	1027	purpose	purpose	NN	I-NP
O	1028	1031	was	be	VBD	B-VP
O	1032	1034	to	to	TO	B-VP
O	1035	1042	examine	examine	VB	I-VP
O	1043	1048	human	human	JJ	B-NP
B-Cancer	1049	1054	colon	colon	NN	I-NP
I-Cancer	1055	1062	cancers	cancer	NNS	I-NP
O	1063	1066	for	for	IN	B-PP
O	1067	1079	inactivation	inactivation	NN	B-NP
O	1080	1082	of	of	IN	B-PP
O	1083	1086	two	two	CD	B-NP
O	1087	1096	candidate	candidate	NN	I-NP
O	1097	1107	metastasis	metastasis	NN	I-NP
O	1108	1118	suppressor	suppressor	NN	I-NP
O	1119	1124	genes	gene	NNS	I-NP
O	1124	1125	,	,	,	O
O	1126	1130	nm23	nm23	NN	B-NP
O	1130	1131	-	-	HYPH	B-NP
O	1131	1133	H1	H1	NN	I-NP
O	1134	1137	and	and	CC	I-NP
O	1138	1142	nm23	nm23	NN	I-NP
O	1142	1143	-	-	HYPH	B-NP
O	1143	1145	H2	H2	NN	I-NP
O	1145	1146	,	,	,	O
O	1147	1153	either	either	CC	B-PP
O	1154	1156	by	by	IN	I-PP
O	1157	1165	mutation	mutation	NN	B-NP
O	1166	1168	or	or	CC	B-PP
O	1169	1171	by	by	IN	B-PP
O	1172	1176	loss	loss	NN	B-NP
O	1177	1179	of	of	IN	B-PP
O	1180	1184	gene	gene	NN	B-NP
O	1185	1198	transcription	transcription	NN	I-NP
O	1198	1199	.	.	.	O

O	1200	1207	METHODS	METHODS	NNS	B-NP
O	1207	1208	:	:	:	O
O	1209	1211	We	We	PRP	B-NP
O	1212	1216	used	use	VBD	B-VP
O	1217	1229	ribonuclease	ribonuclease	NN	B-NP
O	1230	1240	protection	protection	NN	I-NP
O	1241	1247	assays	assay	NNS	I-NP
O	1248	1250	to	to	TO	B-VP
O	1251	1258	analyze	analyze	VB	I-VP
O	1259	1264	human	human	JJ	B-NP
B-Cancer	1265	1270	colon	colon	NN	I-NP
I-Cancer	1271	1277	tumors	tumor	NNS	I-NP
O	1278	1281	for	for	IN	B-PP
O	1282	1285	the	the	DT	B-NP
O	1286	1291	level	level	NN	I-NP
O	1292	1294	of	of	IN	B-PP
O	1295	1299	nm23	nm23	NN	B-NP
O	1299	1300	-	-	HYPH	O
O	1300	1302	H1	H1	NN	B-NP
O	1303	1304	(	(	(	O
O	1304	1306	43	43	CD	B-NP
B-Cancer	1307	1314	samples	sample	NNS	I-NP
O	1314	1315	)	)	)	O
O	1316	1319	and	and	CC	O
O	1320	1324	nm23	nm23	NN	B-NP
O	1324	1325	-	-	HYPH	O
O	1325	1327	H2	H2	NN	B-NP
O	1328	1329	(	(	(	O
O	1329	1331	41	41	CD	B-NP
B-Cancer	1332	1339	samples	sample	NNS	I-NP
O	1339	1340	)	)	)	O
O	1341	1351	transcript	transcript	NN	B-NP
O	1352	1353	(	(	(	O
O	1353	1357	mRNA	mRNA	NN	B-NP
O	1357	1358	)	)	)	O
O	1359	1369	expression	expression	NN	B-NP
O	1370	1373	and	and	CC	O
O	1374	1377	the	the	DT	B-NP
O	1378	1386	presence	presence	NN	I-NP
O	1387	1389	of	of	IN	B-PP
O	1390	1399	mutations	mutation	NNS	B-NP
O	1400	1404	that	that	WDT	B-NP
O	1405	1410	could	could	MD	B-VP
O	1411	1421	inactivate	inactivate	VB	I-VP
O	1422	1431	potential	potential	JJ	B-NP
O	1432	1442	suppressor	suppressor	NN	I-NP
O	1443	1451	function	function	NN	I-NP
O	1451	1452	.	.	.	O

O	1453	1460	RESULTS	RESULTS	NNS	B-NP
O	1460	1461	:	:	:	O
O	1462	1464	We	We	PRP	B-NP
O	1465	1473	detected	detect	VBD	B-VP
O	1474	1478	only	only	RB	B-NP
O	1479	1483	wild	wild	JJ	I-NP
O	1483	1484	-	-	HYPH	I-NP
O	1484	1488	type	type	NN	I-NP
O	1489	1493	nm23	nm23	NN	I-NP
O	1493	1494	-	-	HYPH	B-NP
O	1494	1496	H1	H1	NN	I-NP
O	1497	1500	and	and	CC	I-NP
O	1501	1505	nm23	nm23	NN	I-NP
O	1505	1506	-	-	HYPH	B-NP
O	1506	1508	H2	H2	NN	I-NP
O	1509	1513	mRNA	mRNA	NN	I-NP
O	1513	1514	.	.	.	O

O	1515	1525	Expression	Expression	NN	B-NP
O	1526	1528	of	of	IN	B-PP
O	1529	1533	nm23	nm23	NN	B-NP
O	1533	1534	-	-	HYPH	B-NP
O	1534	1536	H1	H1	NN	I-NP
O	1537	1541	mRNA	mRNA	NN	I-NP
O	1542	1551	increased	increase	VBD	B-VP
O	1552	1554	in	in	IN	B-PP
O	1555	1557	33	33	CD	B-NP
O	1558	1560	of	of	IN	B-PP
O	1561	1563	41	41	CD	B-NP
B-Cancer	1564	1569	colon	colon	NN	I-NP
I-Cancer	1570	1576	tumors	tumor	NNS	I-NP
O	1576	1577	,	,	,	O
O	1578	1581	and	and	CC	O
O	1582	1592	expression	expression	NN	B-NP
O	1593	1595	of	of	IN	B-PP
O	1596	1600	nm23	nm23	NN	B-NP
O	1600	1601	-	-	HYPH	B-NP
O	1601	1603	H2	H2	NN	I-NP
O	1604	1608	mRNA	mRNA	NN	I-NP
O	1609	1612	was	be	VBD	B-VP
O	1613	1621	elevated	elevate	VBN	I-VP
O	1622	1624	in	in	IN	B-PP
O	1625	1627	28	28	CD	B-NP
O	1628	1630	of	of	IN	B-PP
O	1631	1633	41	41	CD	B-NP
B-Cancer	1634	1639	colon	colon	NN	I-NP
I-Cancer	1640	1646	tumors	tumor	NNS	I-NP
O	1647	1655	relative	relative	JJ	B-ADVP
O	1656	1658	to	to	TO	B-PP
O	1659	1663	that	that	DT	B-NP
O	1664	1666	in	in	IN	B-PP
O	1667	1674	matched	match	VBN	B-NP
O	1675	1681	normal	normal	JJ	I-NP
B-Multi-tissue_structure	1682	1688	mucosa	mucosa	NN	I-NP
O	1688	1689	.	.	.	O

O	1690	1699	Increases	Increase	NNS	B-NP
O	1700	1702	in	in	IN	B-PP
O	1703	1708	these	these	DT	B-NP
O	1709	1713	mRNA	mRNA	NN	I-NP
O	1714	1720	levels	level	NNS	I-NP
O	1721	1725	were	be	VBD	B-VP
O	1726	1733	similar	similar	JJ	B-ADJP
O	1734	1736	in	in	IN	B-PP
B-Cancer	1737	1743	tumors	tumor	NNS	B-NP
O	1744	1746	of	of	IN	B-PP
O	1747	1751	both	both	CC	B-NP
O	1752	1755	low	low	JJ	I-NP
O	1756	1759	and	and	CC	I-NP
O	1760	1764	high	high	JJ	I-NP
O	1765	1775	metastatic	metastatic	JJ	I-NP
O	1776	1785	potential	potential	NN	I-NP
O	1785	1786	.	.	.	O

O	1787	1798	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1798	1799	:	:	:	O
O	1800	1805	These	These	DT	B-NP
O	1806	1813	results	result	NNS	I-NP
O	1814	1821	suggest	suggest	VBP	B-VP
O	1822	1826	that	that	IN	B-SBAR
O	1826	1827	,	,	,	O
O	1828	1835	despite	despite	IN	B-PP
O	1836	1847	correlation	correlation	NN	B-NP
O	1848	1850	of	of	IN	B-PP
O	1851	1855	nm23	nm23	NN	B-NP
O	1855	1856	-	-	HYPH	B-NP
O	1856	1858	H1	H1	NN	I-NP
O	1859	1866	allelic	allelic	JJ	I-NP
O	1867	1876	deletions	deletion	NNS	I-NP
O	1877	1881	with	with	IN	B-PP
B-Cancer	1882	1887	colon	colon	NN	B-NP
I-Cancer	1888	1895	cancers	cancer	NNS	I-NP
O	1896	1906	associated	associate	VBN	B-VP
O	1907	1911	with	with	IN	B-PP
O	1912	1916	poor	poor	JJ	B-NP
O	1917	1926	prognosis	prognosis	NN	I-NP
O	1926	1927	,	,	,	O
O	1928	1932	nm23	nm23	NN	B-NP
O	1932	1933	-	-	HYPH	B-NP
O	1933	1935	H1	H1	NN	I-NP
O	1936	1939	and	and	CC	I-NP
O	1940	1944	nm23	nm23	NN	I-NP
O	1944	1945	-	-	HYPH	B-NP
O	1945	1947	H2	H2	NN	I-NP
O	1948	1955	alleles	allele	NNS	I-NP
O	1956	1958	do	do	VBP	B-VP
O	1959	1962	not	not	RB	I-VP
O	1963	1971	directly	directly	RB	I-VP
O	1972	1979	mediate	mediate	VB	I-VP
O	1980	1990	metastasis	metastasis	NN	B-NP
O	1991	2002	suppression	suppression	NN	I-NP
O	2003	2005	in	in	IN	B-PP
B-Cancer	2006	2011	colon	colon	NN	B-NP
I-Cancer	2012	2021	carcinoma	carcinoma	NN	I-NP
O	2021	2022	.	.	.	O

O	2023	2026	Our	Our	PRP$	B-NP
O	2027	2034	results	result	NNS	I-NP
O	2035	2040	leave	leave	VBP	B-VP
O	2041	2052	unexplained	unexplained	JJ	B-ADJP
O	2053	2056	the	the	DT	B-NP
O	2057	2068	observation	observation	NN	I-NP
O	2069	2073	that	that	IN	B-SBAR
O	2074	2078	nm23	nm23	NN	B-NP
O	2078	2079	-	-	HYPH	B-NP
O	2079	2081	H1	H1	NN	I-NP
O	2082	2089	allelic	allelic	JJ	I-NP
O	2090	2098	deletion	deletion	NN	I-NP
O	2099	2109	correlates	correlate	VBZ	B-VP
O	2110	2114	with	with	IN	B-PP
O	2115	2125	metastatic	metastatic	JJ	B-NP
O	2126	2135	potential	potential	NN	I-NP
O	2136	2138	of	of	IN	B-PP
B-Cancer	2139	2144	colon	colon	NN	B-NP
I-Cancer	2145	2155	carcinomas	carcinoma	NNS	I-NP
O	2155	2156	.	.	.	O

O	2157	2169	IMPLICATIONS	IMPLICATIONS	NNS	B-NP
O	2169	2170	:	:	:	O
O	2171	2176	These	These	DT	B-NP
O	2177	2185	findings	finding	NNS	I-NP
O	2186	2190	also	also	RB	B-ADVP
O	2191	2199	contrast	contrast	VBP	B-VP
O	2200	2204	with	with	IN	B-PP
O	2205	2208	the	the	DT	B-NP
O	2209	2222	demonstration	demonstration	NN	I-NP
O	2223	2225	of	of	IN	B-PP
O	2226	2230	nm23	nm23	NN	B-NP
O	2231	2241	metastasis	metastasis	NN	I-NP
O	2242	2252	suppressor	suppressor	NN	I-NP
O	2253	2261	activity	activity	NN	I-NP
O	2262	2264	in	in	IN	B-PP
O	2265	2271	murine	murine	JJ	B-NP
B-Cancer	2272	2280	melanoma	melanoma	NN	I-NP
O	2281	2284	and	and	CC	B-PP
O	2285	2289	with	with	IN	B-PP
O	2290	2293	the	the	DT	B-NP
O	2294	2305	correlation	correlation	NN	I-NP
O	2306	2308	of	of	IN	B-PP
O	2309	2313	loss	loss	NN	B-NP
O	2314	2316	of	of	IN	B-PP
O	2317	2321	nm23	nm23	NN	B-NP
O	2322	2332	expression	expression	NN	I-NP
O	2333	2335	in	in	IN	B-PP
B-Cancer	2336	2342	breast	breast	NN	B-NP
I-Cancer	2343	2349	cancer	cancer	NN	I-NP
O	2350	2354	with	with	IN	B-PP
O	2355	2359	poor	poor	JJ	B-NP
O	2360	2369	prognosis	prognosis	NN	I-NP
O	2369	2370	.	.	.	O

O	2371	2373	It	It	PRP	B-NP
O	2374	2377	may	may	MD	B-VP
O	2378	2380	be	be	VB	I-VP
O	2381	2385	that	that	IN	B-SBAR
O	2386	2396	metastasis	metastasis	NN	B-NP
O	2397	2408	suppression	suppression	NN	I-NP
O	2409	2411	by	by	IN	B-PP
O	2412	2415	the	the	DT	B-NP
O	2416	2420	nm23	nm23	NN	I-NP
O	2421	2425	gene	gene	NN	I-NP
O	2426	2428	is	be	VBZ	B-VP
O	2429	2430	a	a	DT	B-NP
B-Tissue	2431	2437	tissue	tissue	NN	I-NP
O	2437	2438	-	-	HYPH	B-NP
O	2438	2446	specific	specific	JJ	I-NP
O	2447	2457	phenomenon	phenomenon	NN	I-NP
O	2457	2458	.	.	.	O

